The surgical curative time window for lung adenocarcinoma: A comprehensive understanding_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

FU Fangqiu ^1,2 , ZHANG Yang ^1,2 ,  CHEN Haiquan ^1,2

1. Department of Thoracic Surgery, Cancer Hospital Affiliated to Fudan University, Shanghai, 200032, P. R. China;
2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, P. R. China;

Corresponding author：

CHEN Haiquan, Email: hqchen1@yahoo.com

Keywords：

Lung adenocarcinoma; surgical timing; cure; ground-glass opacity; commentary

DOI：

10.7507/1007-4848.202310004

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Recently, an editorial in Cell Research illuminated the concept of the curative time window for lung adenocarcinoma. Within this window, patients could achieve 100.0% 5-year or 10-year post-operative recurrence-free survival. Adenocarcinoma in situ and minimally invasive adenocarcinoma in pathology, as well as pure ground-glass opacity in radiology could be regarded as the curative time window. However, not all the patients can catch this time window. A precise understanding of this concept helps elevate the curative rate for lung cancer patients and mitigate the risks of overdiagnosis and overtreatment. This article delves into the accurate comprehension of the surgical curative time window for lung adenocarcinoma, proposed a clinical strategy for early-stage lung adenocarcinoma, and introduced clinical procedures comprising of this time window. It offers fresh insights into the timing of surgical interventions for lung adenocarcinoma.

Citation： FU Fangqiu, ZHANG Yang, CHEN Haiquan. The surgical curative time window for lung adenocarcinoma: A comprehensive understanding. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(12): 1674-1677. doi: 10.7507/1007-4848.202310004 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	Sihoe ADL. Video-assisted thoracoscopic surgery as the gold standard for lung cancer surgery. Respirology, 2020, 25(Suppl 2): 49-60.
3.	Zhang Y, Jheon S, Li H, et al. Results of low-dose computed tomography as a regular health examination among Chinese hospital employees. J Thorac Cardiovasc Surg, 2020, 160(3): 824-831.
4.	Fu F, Chen Z, Chen H. Treating lung cancer: Defining surgical curative time window. Cell Res, 2023, 33(9): 649-650.
5.	Li D, Deng C, Wang S, et al. Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative . J Thorac Cardiovasc Surg , 2022, 164(6): 1614-1622.
6.	Li D, Deng C, Wang S, et al. Ten-year follow-up results of pure ground-glass opacity-featured lung adenocarcinomas after surgery. Ann Thorac Surg, 2023, 116(2): 230-237.
7.	Travis WD, Brambilla E, Noguchi M, et al. International Aassociation for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011, 6(2): 244-285.
8.	Zhang Y, Fu F, Chen H. Management of ground-glass opacities in the lung cancer spectrum. Ann Thorac Surg, 2020, 110(6): 1796-1804.
9.	Li S, Yi M, Dong B, et al. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer, 2021, 148(11): 2640-2651.
10.	Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: Opportunities and challenges. Ann Oncol, 2021, 32(4): 466-477.
11.	Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol, 2017, 14(9): 531-548.
12.	Burki TK. Predicting lung cancer prognosis using machine learning. Lancet Oncol, 2016, 17(10): e421.
13.	Zhou Y, Xu X, Song L, et al. The application of artificial intelligence and radiomics in lung cancer. Precis Clin Med, 2020, 3(3): 214-227.
14.	Ten Haaf K, van der Aalst CM, de Koning HJ. Clinically detected non-aggressive lung cancers: Implications for overdiagnosis and overtreatment in lung cancer screening. Thorax, 2018, 73(5): 407-408.
15.	Ye T, Deng L, Xiang J, et al. Predictors of pathologic tumor invasion and prognosis for ground glass opacity featured lung adenocarcinoma. Ann Thorac Surg, 2018, 106(6): 1682-1690.
16.	Yang W, Sun Y, Fang W, et al. High-resolution computed tomography features distinguishing benign and malignant lesions manifesting as persistent solitary subsolid nodules. Clin Lung Cancer, 2018, 19(1): e75-e83.
17.	Kakinuma R, Noguchi M, Ashizawa K, et al. Natural history of pulmonary subsolid nodules: A prospective multicenter study. J Thorac Oncol, 2016, 11(7): 1012-1028.
18.	Cheng X, Onaitis MW, D'Amico TA, et al. Minimally invasive thoracic surgery 3.0: Lessons learned from the history of lung cancer surgery. Ann Surg, 2018, 267(1): 37-38.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. Sihoe ADL. Video-assisted thoracoscopic surgery as the gold standard for lung cancer surgery. Respirology, 2020, 25(Suppl 2): 49-60.
3. Zhang Y, Jheon S, Li H, et al. Results of low-dose computed tomography as a regular health examination among Chinese hospital employees. J Thorac Cardiovasc Surg, 2020, 160(3): 824-831.
4. Fu F, Chen Z, Chen H. Treating lung cancer: Defining surgical curative time window. Cell Res, 2023, 33(9): 649-650.
5. Li D, Deng C, Wang S, et al. Ten-year follow-up of lung cancer patients with resected adenocarcinoma in situ or minimally invasive adenocarcinoma: Wedge resection is curative . J Thorac Cardiovasc Surg , 2022, 164(6): 1614-1622.
6. Li D, Deng C, Wang S, et al. Ten-year follow-up results of pure ground-glass opacity-featured lung adenocarcinomas after surgery. Ann Thorac Surg, 2023, 116(2): 230-237.
7. Travis WD, Brambilla E, Noguchi M, et al. International Aassociation for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol, 2011, 6(2): 244-285.
8. Zhang Y, Fu F, Chen H. Management of ground-glass opacities in the lung cancer spectrum. Ann Thorac Surg, 2020, 110(6): 1796-1804.
9. Li S, Yi M, Dong B, et al. The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer, 2021, 148(11): 2640-2651.
10. Yu W, Hurley J, Roberts D, et al. Exosome-based liquid biopsies in cancer: Opportunities and challenges. Ann Oncol, 2021, 32(4): 466-477.
11. Siravegna G, Marsoni S, Siena S, et al. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol, 2017, 14(9): 531-548.
12. Burki TK. Predicting lung cancer prognosis using machine learning. Lancet Oncol, 2016, 17(10): e421.
13. Zhou Y, Xu X, Song L, et al. The application of artificial intelligence and radiomics in lung cancer. Precis Clin Med, 2020, 3(3): 214-227.
14. Ten Haaf K, van der Aalst CM, de Koning HJ. Clinically detected non-aggressive lung cancers: Implications for overdiagnosis and overtreatment in lung cancer screening. Thorax, 2018, 73(5): 407-408.
15. Ye T, Deng L, Xiang J, et al. Predictors of pathologic tumor invasion and prognosis for ground glass opacity featured lung adenocarcinoma. Ann Thorac Surg, 2018, 106(6): 1682-1690.
16. Yang W, Sun Y, Fang W, et al. High-resolution computed tomography features distinguishing benign and malignant lesions manifesting as persistent solitary subsolid nodules. Clin Lung Cancer, 2018, 19(1): e75-e83.
17. Kakinuma R, Noguchi M, Ashizawa K, et al. Natural history of pulmonary subsolid nodules: A prospective multicenter study. J Thorac Oncol, 2016, 11(7): 1012-1028.
18. Cheng X, Onaitis MW, D'Amico TA, et al. Minimally invasive thoracic surgery 3.0: Lessons learned from the history of lung cancer surgery. Ann Surg, 2018, 267(1): 37-38.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

The surgical curative time window for lung adenocarcinoma: A comprehensive understanding

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content